Liraglutide, a glucagon-like peptide receptor agonist (GLP1-RA), shares high amino acid sequence homology with GLP-1, was first approved for type 2 diabetes and later approved for treatment of common obesity; it reduces appetite and leads to weight loss in obesity caused by MC4R pathogenic variants. The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.